-
Net Sales are expected to decrease by 7.8 percent Y-o-Y (up 11.9 percent Q-o-Q) to Rs 1,443 crore, according to ICICI Direct.
-
Net Sales are expected to decrease by 7.3 percent Y-o-Y (up 12.6 percent Q-o-Q) to Rs 1,451.7 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to increase by 14.6 percent Y-o-Y (down 10.7 percent Q-o-Q) to Rs 1,277 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to decrease by 2.2 percent Y-o-Y (down 10.8 percent Q-o-Q) to Rs 1,378.3 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to increase by 10.7 percent Y-o-Y (down 2.8 percent Q-o-Q) to Rs 1,437.2 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to decrease by 13.9 percent Y-o-Y (up 18.6 percent Q-o-Q) to Rs 1321.4 crore, according to ICICI Direct.
-
Net Sales are expected to increase by 21.1 percent Y-o-Y (down 7.8 percent Q-o-Q) to Rs. 1,300 crore, according to Sharekhan.
-
IPCA continues to strive for vertical integration of its formulation production to the level of KSM (Key Starting Material). As of now, more than 60 percent of APIs used for formulations are produced in-house
-
Net Sales are expected to increase by 3.8 percent Y-o-Y (down 7.5 percent Q-o-Q) to Rs. 1,259 crore, according to Yash Securities.
-
Net Sales are expected to increase by 12.8 percent Y-o-Y (up 11.3 percent Q-o-Q) to Rs. 1,125.4 crore, according to Emkay.
-
Net Sales are expected to increase by 14 percent Y-o-Y (up 16.8 percent Q-o-Q) to Rs. 973.5 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to increase by 24.2 percent Y-o-Y (up 2.5 percent Q-o-Q) to Rs. 970.8 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to increase by 9.3 percent Y-o-Y (down 7.3 percent Q-o-Q) to Rs. 939.1 crore, according to ICICI Direct.
-
Net Sales are expected to increase by 10 percent Y-o-Y (up 11.3 percent Q-o-Q) to Rs. 950.5 crore, according to ICICI Direct.
-
Net Sales are expected to increase by 19.4 percent Y-o-Y (down 7.5 percent Q-o-Q) to Rs. 795.1 crore, according to Edelweiss.
-
Net Sales are expected to increase by 34.5 percent Q-o-Q (up 10.9 percent Y-o-Y) to Rs 840.4 crore, according to Edelweiss
-
Sarabjit Kaur Nangra of Angel Broking says the stock is very well valued at the current prices and adds that the company‘s cautiousness about maintaining its profitability is a positive.
-
Pharma companies are likely to post 12 percent Y-o-Y revenue growth. However, excluding Wockhardt (FDA issues) and Fortis Healthcare (divestments), revenue growth is expected to be 19 percent Y-o-Y.
-
Ipca Labs hopes to continue doing very well in H2FY14 especially in its India formulation business, says ED AK Jain. It is awating USFDA approvals for Indore SEZ which, the company feels will boost its business going forward.
-
AK Jain, ED, Ipca Labs told CNBC-TV18 that the start of the earnings for the company is very good and down the line maybe after Q2 it may revise the guidance.
-
Motilal Oswal has come with its March`13 quarterly earning estimates for healthcare sector. The research firm expects a top line growth of 17.4% YoY and EBITDA growth of 21.3% YoY for our pharma universe (excluding one-offs).
-
Last week, Ipca Laboratories reported net profit of Rs 87.89 crore for the quarter ending December 31, 2012 on the back of strong sales across domestic and international markets. AK Jain, ED, Ipca Laboratories told CNBC-TV18 that the margins are going to remain in the regions of around 32 percent plus.
-
Nirmal Bang has come out with its earnings estimates for pharmaceutical sector for the quarter ended December 2012. The research firm feels margins of pharma companies may witness YoY expansion owing to rupee depreciation (6 percent YoY).
-
Motilal Oswal has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects the topline to grow by 22 percent, EBITDA by 21 percent on the back of strong operational performance by Ranbaxy, Glenmark, Strides, Torrent and Divi's.
-
Prabhudas Lilladher has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects top-line growth of 24 percent YoY for its coverage universe (excluding one-offs), with EBITDA growth at a robust 24 percent YoY.
